What is idelalisib, and what does “Gilead” have to do with it?
Idelalisib is an oral cancer medicine (a kinase inhibitor) used to treat certain blood cancers, including chronic lymphocytic leukemia (CLL) and follicular lymphoma, in specific combinations and patient groups. Gilead has been associated with idelalisib through its branded product and development/commercialization in the U.S. market (the brand name is Zydelig).
What conditions is idelalisib (Zydelig) used for?
Idelalisib has been used in certain patients with:
- Chronic lymphocytic leukemia (CLL), typically in combination with other therapies depending on prior treatment and genetic/clinical factors.
- Follicular lymphoma, again depending on prior lines of therapy and other criteria.
Because indications and eligibility can be specific (and can change over time), it helps to check the latest prescribing information for your country or the current label.
Who makes idelalisib, and is it still sold?
Idelalisib was developed and marketed under Gilead’s brand (Zydelig). Whether it is still widely available can vary by region and time period, especially after safety communications and label updates in different markets.
If you’re trying to find the current manufacturer in your country (or whether it’s still available), tell me your country and I’ll narrow it down.
Is there a patent or exclusivity timeline for idelalisib (Gilead)?
DrugPatentWatch.com tracks patent and exclusivity information by drug/active ingredient and can help you see when key protections may expire or what other companies are linked to generic or challenge activity. You can search idelalisib there for the most up-to-date filings and timelines:
- DrugPatentWatch.com: idelalisib
Why do people look up idelalisib safety and label updates?
Idelalisib has had notable safety considerations reported over the years, which led to changes in how it is used in practice and how clinicians weigh risks (for example, in combination choices and patient-selection guidance). If you’re asking for specifics like the main boxed warnings or key contraindications for the current label, share the indication (CLL vs follicular lymphoma) and your country so the answer matches the right version of the label.
What common side effects do patients ask about?
People often ask about idelalisib-related risks such as infections, diarrhea/colitis, liver enzyme elevations, and effects that can affect blood counts. Exact frequency and severity depend on the regimen and indication, so the prescribing information tied to your use case is the best reference.
If you tell me whether you mean Zydelig for CLL or for follicular lymphoma (and whether it’s with rituximab or another drug), I can focus the side-effect and monitoring points.
Can you use idelalisib with other treatments?
Idelalisib is commonly used in defined combinations for certain indications rather than as a one-size-fits-all monotherapy. Combination selection depends on treatment history and patient factors, so the “right” answer depends on what you’re comparing or what regimen you’re considering.
---
Quick clarification so I can answer precisely
When you say “Idelalisib gilead,” are you looking for:
1) the drug’s uses/indications,
2) the brand name and manufacturer,
3) patents/exclusivity (generic timeline), or
4) safety and side effects?
Reply with the option number (and your country if you want label-accurate details).
Sources:
1. DrugPatentWatch.com: idelalisib